BioCentury's streaming commentary on industry trends, plus interviews with leading KOLs.
Listen to BioCentury This Week on your favorite podcast service.
Podcast sponsorship opportunities are available. Contact Sarah Shoaff.
BioCentury This Week podcast also features the latest strategies for optimizing the potency of TCR-based cancer therapies
BioCentury’s latest podcast discusses how Biogen’s next head of R&D should think about the biotech’s therapeutic focus
Biotech leaders from three continents, Debra Yu, Henk Joos and David Oxley, discuss RWE, medtech, precision medicine and China’s role in global deals
Jones Day’s Chen, McKinsey’s Zhang discuss the evolution of China’s biotech ecosystem
BioCentury’s latest podcast examines the priorities of FDA’s likely next commissioner
BeiGene’s Xiaobin Wu, Zai Lab’s Billy Cho on company priorities, finding talent and future bellwethers among China’s innovators
Build Back Better’s drug pricing provisions are likely to change investment decisions; it has a long road ahead
Emerging Company Spotlight: MoonLake, Walden
Emerging Company Spotlight: Elpiscience and Rectify
It’s been a year of setbacks spanning safety, efficacy and access, but the future looks bright
Can Biogen push another neurodegeneration therapy across the goal line at FDA?
Plus Novartis CEO’s view of translational science and this week’s Deal in Focus, Flexion-Pacira
BioCentury’s editors also discuss the implications of Catalyst’s win over FDA in court and the latest in translation
The SEHK’s biotech chapter three years on